

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/026004
	Serial No.	10/670,488
	Applicant	Jost-Price et al.
	Filing Date	September 24, 2003
	Group	1617
	IDS Filed	March 4, 2009

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,833,998	Nov. 10, 1998	Biedermann et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Franklin, "Clinical Experience with Soluble TNF p75 Receptor in Rheumatoid Arthritis," <i>Semin. Arthritis Rheum.</i> 29:172-181, 1999.
	Kumar et al., "Fatal Haemorrhagic Pulmonary Oedema and Associated Angiodema After the Ingestion of Rofecoxib," <i>Postgrad. Med. J.</i> 78:439-440, 2002.
	Sandky, "Impairment of Depth Perception in Multiple Sclerosis is Improved by Treatment with AC Pulsed Electromagnetic Fields," <i>Int. J. Neurosci.</i> 98:83-94, 1999.

EXAMINER	/Sahar Javanmard/	DATE CONSIDERED	03/30/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./